Artificial intelligence (AI) is becoming a potential model
that uses human knowledge to solve difficult problems more quickly. The field
of drug discovery, pharmaceutical formulation, and dosage form testing is about
to undergo a radical change because of remarkable developments in AI and
machine learning. Researchers may find disease-associated targets and
anticipate how they would interact with possible treatment options by using
AI-developed programs that examine vast biological data like proteomics and genomics.
This raises the likelihood of successful pharmaceutical approvals by allowing
for an efficientive and concentrated approach to drug development. AI may also
save development costs by streamlining the research and development process. AI
models enable pharmaceutical companies to design, automate, evaluate, and
monitor human-centric and integration-centric activities and processes, helping
them to deliver novel medicines more cost-effectively and on time. It improves
repeatability, control, and visibility inside the firm while also streamlining
and simplifying operations. It may help pharmaceutical manufacturers quickly
understand and implement procedures and systems to improve their company
operations, offering them the agility they require to respond to changing
situations, new legislation, and expectations for a short product delivery
life-cycle. Artificial intelligence evaluates patient information and enables
the personalization of medicine approaches, hence improving patient adherence
and treatment outcomes. This thorough overview section delves into the many
uses of AI in the creation of drug delivery, formulation development, process
optimization, evaluation, and PK/PD studies. The article discusses the benefits
and drawbacks of several AI model strategies applying in pharmaceutical
manufacturing. However, the pharmaceutical industry's increasing research and
investment in AI creates several prospects for enhancing the treatment of
patients and drug development processes.
Author(s) Details:
Dr. Kotha Kranthi
Kumar (Associate Professor)
Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda
Sagar University, Bengaluru, Karnataka, India.
Mrs. Jyothi M.
(Associate Professor)
Department of Pharmaceutics, East Point College of Pharmacy, East Point
Group of Institutions, Jnana Prabha, East Point Campus, Virgo Nagar,
Bidarahalli, Karnataka, India.
Please see the book here:
https://doi.org/10.9734/bpi/prrat/v1/194
No comments:
Post a Comment